Sorilux Approval History
Sorilux (calcipotriene) is a vitamin D analog indicated for the topical treatment of plaque psoriasis in patients 12 years and older.
Development History and FDA Approval Process for Sorilux
|May 22, 2019||FDA Approves Sorilux for Adolescent Plaque Psoriasis|
|Oct 12, 2010||Stiefel, a GSK company, Receives FDA Approval of Sorilux (calcipotriene) Foam, 0.005%|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.